Neurocrine Biosciences (NBIX) Cash from Operations (2010 - 2026)

Neurocrine Biosciences' Cash from Operations history runs 17 years deep, the most recent figure standing at 145800000.0 for Q1 2026.

• Quarterly Cash from Operations rose 125.0% year-over-year to 145800000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 863700000.0 (up 62.99% YoY) and the FY2025 annual result came in at 782700000.0, up 31.46% from the prior year.
• Cash from Operations was 145800000.0 for Q1 2026 at Neurocrine Biosciences, down from 388400000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 388400000.0 in Q4 2025 and bottomed at 125200000.0 in Q1 2023.
• A 5-year average of 132541176.47 and a median of 138100000.0 in 2022 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2022 — Cash from Operations soared 3304.76% — and 2023, when it tumbled 209.14%.
• Neurocrine Biosciences' Cash from Operations stood at 143000000.0 in 2022, then dropped by 13.64% to 123500000.0 in 2023, then jumped by 96.36% to 242500000.0 in 2024, then soared by 60.16% to 388400000.0 in 2025, then tumbled by 62.46% to 145800000.0 in 2026.
• Business Quant data shows NBIX's Cash from Operations at 145800000.0 in Q1 2026, 388400000.0 in Q4 2025, and 227500000.0 in Q3 2025.